ClinicalTrials.gg
CompletedNCT05902962PlatypusUpdated May 29, 2026

SAD of IVT VP-001 in PRPF31 Mutation-Associated Retinal Dystrophy Subjects

A Phase 1 interventional study of VP-001 in Retinal Dystrophy, PRPF31 Mutationassociated Retinal Dystrophy and RP11, sponsored by PYC Therapeutics. Completed at 6 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-29.

Sponsored by PYC Therapeutics · Phase 1, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Aug 2025, 1 year 3 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
17
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 27 studies in Retinal Dystrophies with a site in United States — 8 open to participants now, 16 under way, none of them phase 3. Retinal Dystrophies · United States.

Enrollment
9th of 16
17 · median 20
Started
2023
with 4 others
Phase 1
4 of 27
2 open now
Registered
17th of 27
by date
Lead sponsor
4 of 27
PYC Therapeutics

Among the 27 studies in Retinal Dystrophies with a site in United States, this one is the 9th largest by enrollment of the 16 interventional ones that give a count, is one of 5 that started in 2023, is one of 4 in phase 1, and was the 17th registered.

Retinal Dystrophies

60 studies on the registry are indexed under Retinal Dystrophies; 20 are open to participants now.

Browse Retinal Dystrophies studies →

Open to participants now

8 of the 27 studies in Retinal Dystrophies with a site in United States are open now. Recruiting first, the newest first:

3 more — sign in →

All 8 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 17 Retinal Dystrophies studies recruiting now, 11 (65%) set no upper age limit and 3 (18%) stop at 75 or younger; 6 take children under 18; 5 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies in Retinal Dystrophies with a site in United States, or all of them as a file.
02

Study summary

A Phase 1 Open-Label, Single Arm Dose Escalation Study to Evaluate the Safety and Tolerability of Intravitreally Administered VP-001 in Participants with Confirmed PRPF31 Mutation-Associated Retinal Dystrophy

03

Conditions studied

  • Retinal Dystrophy
  • PRPF31 Mutationassociated Retinal Dystrophy
  • RP11

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female sex; ≥ 18 years of age at Baseline (Visit 2).
  2. Have a molecular (genetic) diagnosis of PRPF31 mutation.
  3. Have a clinical diagnosis of PRPF31 mutation-associated retinal dystrophy, that is, RP11. The following conditions are allowed for inclusion if due to RP11, if in the opinion of the investigator they will not interfere with study evaluations or have resolved: macular edema (intraretinal, sub-retinal or other fluid) requiring regular treatment at a frequency of less than every 6 weeks; macular edema must be stable for at least 3 months prior to Screening (Visit 1). The investigator must consult with the study Medical Monitor.
  4. If ≥ 18 years of age, understand the language of the and are willing and able to provide written informed consent prior to any study procedures. Are willing to comply with the instructions and attend all scheduled study visits.

6. Have light perception (LP) or better vision in the study eye. 7. Participants of and male participants must not be pregnant or lactating and must be sexually inactive by abstinence, which is consistent with the preferred and usual lifestyle of the participant or agree to use adequate throughout study duration. Adequate birth control is defined as hormonal - oral, implantable, injectable, or transdermal contraceptives; mechanical - spermicide in conjunction with a barrier such as a condom or diaphragm; intrauterine device (IUD); or surgical sterilization of partner. For nonsexually active participants, abstinence may be regarded as an adequate method of birth control. Participants of childbearing potential include all participants who have experienced menarche and have not undergone successful surgical sterilization (bilateral tubal ligation, hysterectomy, or bilateral oophorectomy) or are not (12 months after last menses).

Exclusion criteria

Exclusion Criteria:

  1. Have any uncontrolled systemic disease that, in the opinion of the Investigator, would preclude participation in the study that include but are not limited to infection, uncontrolled elevated blood pressure, cardiovascular disease, or glycemic control issues, or any other medical condition that may put the participant at risk due to study procedures.
  2. Mutations in genes that cause autosomal dominant RP, X-linked RP, or presence of biallelic mutations in autosomal recessive RP/retinal dystrophy genes other than PRPF31 mutations.
  3. Have used anti-vascular endothelial growth factor (VEGF) agents within 2 months or injections within the last 3 months.
  4. Have had Ozurdex® implants placed within 3 months or Retisert® or Iluvien® implants placed within 3 years prior to Baseline (Visit 2).
  5. Within 3 months prior to Baseline (Visit 2), have undergone any vitreoretinal surgery (scleral buckle, pars plana vitrectomy, retrieval of a dropped nucleus or intraocular lens, radial optic neurotomy, sheathotomy, cyclodestructive procedures or multiple filtration surgeries [2 or more]) or any other ocular surgery.
  6. Have ocular media opacity or poor pupillary dilation prohibiting quality ophthalmic evaluation or photography, as assessed by the investigator.
  7. Have used any drug or device within 90 days or 5 estimated half-lives of Baseline (Visit 2), whichever is longer, or plan to participate in another study of drug or device during the study period. Participation in observational trials is allowable based on investigator discretion and consultation with the Medical Monitor. It is assumed that the observational trial evaluations would not interfere with participation in this study.
  8. Have received any prior cell or gene therapy for a retinal condition.
  9. Have a recent history (\<6 months) or current excessive recreational drug or alcohol use, in the opinion of the investigator.
  10. Any retinal pathology other than RP11 that in the investigator's opinion could affect study results.
  11. Participants should not have any conditions, in the investigator's opinion, that may put the participant at increased risk, confound study data, or interfere significantly with the participant's study participation.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    Single arm dose escalation study of VP-001

    Drug: VP-001

Interventions

  • DrugVP-001

    Phase 1 open-label, single arm dose escalation study of VP-001 in participants with genetically confirmed PRPF31 mutation-associated retinal dystrophy

06

What researchers measure

Primary outcomes

  1. The incidence, severity, and relatedness of treatment-emergent ocular adverse events (TEAEs) and treatment-emergent serious adverse events (TE-SAEs) in the study eye

    Time frame: over a 24-week time period

  2. The incidence, severity, and relatedness of treatment-emergent ocular adverse events (TEAEs) and treatment-emergent serious adverse events (TE-SAEs) in the study eye

    Time frame: over a 48-week time period

Secondary outcomes

  1. Adverse Events and Treatment Emergent Serious adverse events (SAEs) in the fellow eye

    Time frame: over a 24-week time period

  2. Adverse Events and Treatment Emergent serious adverse events (SAEs) in the fellow eye

    Time frame: over a 48-week time period

  3. Incidence, severity relatedness and of non-ocular TEAEs

    Time frame: over a 24-week time period

  4. Incidence, severity relatedness and of non-ocular TEAEs

    Time frame: over a 48-week time period

Other outcomes

  1. Change from Baseline in Best-corrected visual acuity (BCVA) letter score using Early Treatment Diabetic Retinopathy Study (ETDRS) charts

    Time frame: over a 24-week time period

  2. Change from Baseline in Best-corrected visual acuity (BCVA) letter score using Early Treatment Diabetic Retinopathy Study (ETDRS) charts

    Time frame: over a 48-week time period

  3. Change from Baseline in lowest passing light level using Ora-VNC™ mobility test

    Time frame: over a 24-week time period

  4. Change from Baseline in lowest passing light level using Ora-VNC™ mobility test

    Time frame: over a 48-week time period

  5. Change from Baseline in Low luminance visual acuity (LLVA) letter score

    Time frame: over a 24-week time period

  6. Change from Baseline in Low luminance visual acuity (LLVA) letter score

    Time frame: over a 48-week time period

  7. Change from Baseline in Visual field sensitivity as measured by static perimetry with topographic analysis (Hill of Vision)

    Time frame: over a 24-week time period

  8. Change from Baseline in Visual field sensitivity as measured by static perimetry with topographic analysis (Hill of Vision)

    Time frame: over a 48-week time period

  9. Change from Baseline in Mean retinal sensitivity as measured by fundus-guided microperimetry

    Time frame: over a 24-week time period

  10. Change from Baseline in Mean retinal sensitivity as measured by fundus-guided microperimetry

    Time frame: over a 48-week time period

  11. Change from Baseline in Visual fields as measured by kinetic perimetry, utilizing I4e, III4e and V4e stimuli

    Time frame: over a 24-week time period

  12. Change from Baseline in Visual fields as measured by kinetic perimetry, utilizing I4e, III4e and V4e stimuli

    Time frame: over a 48-week time period

  13. Change from Baseline in Rod- and cone-mediated retinal function as measured by white, red and blue FST

    Time frame: over a 24-week time period

  14. Change from Baseline in Rod- and cone-mediated retinal function as measured by white, red and blue FST

    Time frame: over a 48-week time period

  15. Change from Baseline in Retinal thickness on SD-OCT, including retinal thickness in each ETDRS subfield and ellipsoid zone (EZ) area and volume

    Time frame: over a 24-week time period

  16. Change from Baseline in Retinal thickness on SD-OCT, including retinal thickness in each ETDRS subfield and ellipsoid zone (EZ) area and volume

    Time frame: over a 48-week time period

  17. Change from Baseline in Participant reported outcome measures utilizing the Patient Global Impressions of Change (PGI-C) and Patient Global Impressions of Severity (PGI-S)

    Time frame: over a 24-week time period

  18. Change from Baseline in Participant reported outcome measures utilizing the Patient Global Impressions of Change (PGI-C) and Patient Global Impressions of Severity (PGI-S)

    Time frame: over a 48-week time period

  19. Change from Baseline in Retinal function using full-field electroretinography (ERG)

    Time frame: over a 24-week time period

  20. Change from Baseline in Retinal function using full-field electroretinography (ERG)

    Time frame: over a 48-week time period

  21. Change from Baseline in Area of hypo-autofluorescence captured by FAF

    Time frame: over a 24-week time period

  22. Change from Baseline in Area of hypo-autofluorescence captured by FAF

    Time frame: over a 48-week time period

  23. Change from Baseline in Abnormalities captured by wide-field fundus photography

    Time frame: over a 24-week time period

  24. Change from Baseline in Abnormalities captured by wide-field fundus photography

    Time frame: over a 48-week time period

07

Study locations

6 sites
  • University of Florida Health
    Jacksonville, Florida 32209, United States
  • Bascom Palmer Eye Institute University of Miami
    Miami, Florida 33136, United States
  • University of Michigan Kellogg Eye Center
    Ann Arbor, Michigan 48105, United States
  • Oregon Health and Science University - Casey Eye Institute
    Portland, Oregon 97239, United States
  • Retina Foundation of the Southwest
    Dallas, Texas 75321, United States
  • Baylor College of Medicine- Alkek Eye Center
    Houston, Texas 77030, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2023 to primary completion in Aug 2025, 27 months.

How these figures are worked out, and which studies are left out of them.

Registered
May 25, 2023
First posted
Jun 15, 2023
StartActual
Apr 20, 2023
Primary completionActual
Aug 8, 2025
CompletionActual
Aug 8, 2025
Last update
May 29, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05902962
Lead sponsor
PYC Therapeutics
Responsible party
Sponsor
First posted
Jun 15, 2023
Start date
Apr 20, 2023
Primary completion
Aug 8, 2025
Completion
Aug 8, 2025
Last update
May 29, 2026

Study contacts

Sreenivasu Mudumba
study chair · PYC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: VP-001

Start the discussion